Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration

Next Previous
Search
Trial Profile

OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Aflibercept
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms OASIS
  • Sponsors Clearside Biomedical

    • Most Recent Events

    • 12 Aug 2024 According to a Clearside Biomedical media release, data form this trial published in the Ophthalmology Science.
    • 12 Jun 2024 According to a Clearside Biomedical media release, data form this trial will be presented at the Clinical Trials at the Summit (CTS) Meeting on June 8, 2024 in Park City, Utah.
    • 13 Nov 2023 According to a Clearside Biomedical media release, data from this study were presented at AAO.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top